You are here

PF-06671008 Dose Escalation Study in Advanced Solid Tumors

Last updated on November 14, 2018

FOR MORE INFORMATION
Study Location
Memorial Sloan Kettering Cancer Center - Westchester
Harrison, New York, 10604 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of tumor type with the potential to have P-cadherin expression that is
resistant to standard therapy or for which no standard therapy is available

- Performance status of 0 or 1

- Adequate bone marrow, kidney and liver function

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Known CNS disease including, but not limited to, metastases

- Current or history of seizure disorder

- History of or active autoimmune disorders

- Active bacterial, fungal or viral infection

- Major surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study
treatment

- Requirement for systemic immune suppressive medication

- Grade 2 or greater peripheral neuropathy

NCT02659631
Pfizer
Active, not recruiting
PF-06671008 Dose Escalation Study in Advanced Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06671008 In Patients With Advanced Solid Tumors
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.
Not Provided
Interventional
Phase 1
Masking: None (Open Label)
Primary Purpose: Treatment
Neoplasms
  • Drug: PF-06671008
    Dose Escalation Phase - Part 1
  • Drug: PF-06671008
    Dose Expansion Phase - Part 2
Experimental: PF-06671008
Interventions:
  • Drug: PF-06671008
  • Drug: PF-06671008
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
110
March 2021
March 2021   (Final data collection date for primary outcome measure)

Key Inclusion Criteria

  • Diagnosis of tumor type with the potential to have P-cadherin expression that is resistant to standard therapy or for which no standard therapy is available
  • Performance status of 0 or 1
  • Adequate bone marrow, kidney and liver function

Key Exclusion Criteria

  • Known CNS disease including, but not limited to, metastases
  • Current or history of seizure disorder
  • History of or active autoimmune disorders
  • Active bacterial, fungal or viral infection
  • Major surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study treatment
  • Requirement for systemic immune suppressive medication
  • Grade 2 or greater peripheral neuropathy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
United States
 
 
NCT02659631
B7831001
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now